Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1721-1740 of 1,743 trials

Darolutamide and Bipolar Androgen Therapy for Advanced Prostate Cancer

We are studying whether combining Darolutamide with bipolar androgen therapy improves survival and quality of life for men with metastatic castration-resistant prostate cancer compared to standard treatments.

Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncologyUrology

Tulisokibart for Ankylosing Spondylitis

We are studying a new medication, tulisokibart, to see if it helps people with ankylosing spondylitis feel better compared to a placebo. The trial will assess improvements in pain, function, and overall quality of life.

Ankylosing Spondylitis>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesRheumatology

Cancer Prevention in Lynch Syndrome: Dendritic Cell Therapy

We are testing a new treatment using dendritic cells to help prevent cancer in people with Lynch Syndrome. This study aims to assess its safety and effectiveness in this high-risk group.

Lynch Syndrome>2 yearsSafety phase (I)Internal MedicineOncology

Mantle Cell Lymphoma: Acalabrutinib with R-CHOP

We are studying the combination of acalabrutinib and R-CHOP for patients with previously untreated mantle cell lymphoma. The goal is to see if this combination improves treatment response and is safe.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Type 2 Diabetes: Vicadrostat and Empagliflozin Study

We are testing the combination of vicadrostat and empagliflozin in people with type 2 diabetes, high blood pressure, and heart disease. The goal is to see if this combination can improve heart health compared to a placebo.

Type 2 DiabetesHypertensionCardiovascular Disease>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinologyInternal Medicine

Immunotherapy for Metastatic Colorectal and Prostate Cancer

We are studying a new treatment using patients' own immune cells to see if it is safe and tolerable for those with advanced colorectal or prostate cancer. The trial will help us understand how well this therapy works in these patients.

Locally Advanced or Metastatic Prostate CancerMetastatic Colorectal Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteGastroenterologyOncologyUrology

IVF/ICSI: Low Dose hCG Priming for Women with Diminished Ovarian Reserve

We are investigating whether low dose hCG priming can help women with diminished ovarian reserve retrieve more eggs during IVF/ICSI. This study aims to confirm earlier findings that suggest a significant increase in egg retrieval.

Infertility Due to Diminished Ovarian Reserve>2 yearsConfirmation phase (III)Standard MedicinesGynecology and Obstetrics

Atrial Fibrillation: Early Rhythm-Control Therapy for Stroke Prevention

We are studying if starting rhythm-control therapy early helps patients with atrial fibrillation after a stroke avoid further heart problems. This trial also examines the impact on quality of life and treatment costs.

Acute Ischemic Stroke and Atrial Fibrillation>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Gastrointestinal Tumors: OncoGreen Imaging Study

We are testing a new imaging technique using OncoGreen to help surgeons better visualize tumors during surgery. This study is for patients with gastrointestinal tumors who are having surgery to remove their tumors.

Digestive System Tumors>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyInternal MedicineOncology

Advanced Solid Tumors: EP102 Treatment

We are testing the safety and effectiveness of EP102 in patients with advanced solid tumors. This study aims to see if it can provide better treatment options for these patients.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Durvalumab for Limited Stage Small Cell Lung Cancer

We are studying the safety and effectiveness of durvalumab for patients with limited stage small cell lung cancer who have not progressed after chemoradiation therapy. This trial also looks at how the treatment affects quality of life and disease symptoms.

Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncology

Covert Brain Infarction: Antiplatelet and Lipid-Lowering Treatments

We are studying whether adding antiplatelet and cholesterol-lowering medications can help patients with covert brain infarctions reduce serious health risks. This trial will also assess the impact on cognitive health and overall mortality.

Covert Brain Infarct>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

Gastric Cancer: Intraperitoneal Irinotecan Study

We are exploring a new treatment combining intraperitoneal irinotecan with standard therapy for patients with gastric cancer that has spread to the abdomen. This study aims to evaluate its safety, effectiveness, and impact on quality of life.

Gastric Peritoneal Metastases>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology

Immunotherapy for High-Risk Oral Disorders: APHRODITE Trial

We are testing a new immunotherapy to see if it can prevent high-risk oral disorders from turning into cancer. The study will also look at the treatment's safety and its effects on patients' quality of life.

Oral Disorders>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncologyOtolaryngology

Long-term Safety Study of GD2IL18CART Treatment

We are following up with patients who received GD2IL18CART to check for any long-term safety concerns and to see how well the treatment is working over time, especially in children.

NeuroblastomaOsteosarcomaEwing's Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Advanced-Stage Solid Tumors: JNJ-95437446

We are testing a new treatment for people with advanced-stage solid tumors to see how safe it is and determine the right dosage. This study aims to gather important information for future cancer therapies.

Non-Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Squamous Cell Carcinoma of the Head and Neck (HNSCC)>2 yearsSafety phase (I)Oncology

Cangrelor for Acute Ischemic Stroke Treatment

We are studying the safety and effectiveness of an intravenous medication called Cangrelor for patients with acute ischemic stroke and significant carotid artery blockage. This trial aims to see if it helps improve blood flow during emergency stenting procedures.

Ischemic Stroke with Large Artery Occlusion>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

Zoldonrasib for RAS G12D-Mutant Non-Small Cell Lung Cancer

We are studying the effects of zoldonrasib in patients with RAS G12D-mutant non-small cell lung cancer who have been previously treated. The goal is to see how well it works and how safe it is compared to existing treatments.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Advanced Solid Tumors: MK-1084 Treatment Study

We are studying the effects of MK-1084, both alone and with cetuximab, in patients with advanced solid tumors that have a KRAS G12C mutation. The goal is to see how well these treatments work and how safe they are.

Malignant Neoplasm with KRAS G12C Mutation>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Dilated Cardiomyopathy: AZD4063 Study

We are investigating the safety and effects of AZD4063 in adults with dilated cardiomyopathy due to a specific PLN gene mutation. The study aims to see how the drug works in the body and its impact on PLN mRNA levels.

Dilated Cardiomyopathy>2 yearsSafety phase (I)CardiologyInternal Medicine